CB-13

CB-13
Legal status
Legal status	CA: Schedule II;
Identifiers
	IUPAC name Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone;
CAS Number	432047-72-8 ;
PubChem CID	9799417;
ChemSpider	7975182;
UNII	9XRJ6055XT;
ChEMBL	ChEMBL244403;
CompTox Dashboard (EPA)	DTXSID60430920 ;
Chemical and physical data
Formula	C26H24O2
Molar mass	368.476 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c13ccccc1cccc3C(=O)c4ccc(OCCCCC)c2ccccc24;
	InChI InChI=1S/C26H24O2/c1-2-3-8-18-28-25-17-16-24(21-13-6-7-14-22(21)25)26(27)23-15-9-11-19-10-4-5-12-20(19)23/h4-7,9-17H,2-3,8,18H2,1H3; Key:RSUMDJRTAFBISX-UHFFFAOYSA-N;
	(verify)

CB-13 (CRA13, SAB-378)^[1] is a cannabinoid drug, which acts as a potent agonist at both the CB₁ and CB₂ receptors, but has poor blood–brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies,^[2] and has progressed to preliminary human trials.^[3]